Study To Assess Long Term Safety Of Pazopanib

Key Inclusion Criteria:

- Participated or completed a GSK sponsored pazopanib study and remains eligible for
continued treatment with pazopanib and lapatinib (if on combination therapy).

- Able to understand and provide written informed consent

- Women and men agree to use protocol specific birth control measures

Key Exclusion Criteria:

- The subject has a treatment related serious adverse event that remains unresolved or
unstable or had pazopanib permanently stopped in a previous study because of
intolerate or because it was unsuccessful in treating your cancer

- If you are pregnant or breast feeding

- Your doctor does not think you would be a good candidate for the study

- Poorly controlled high blood pressure

- Subject is unwilling or unable to follow the procedures outlined in the protocol.